NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $72.07 -1.14 (-1.56%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verona Pharma Stock (NASDAQ:VRNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verona Pharma alerts:Sign Up Key Stats Today's Range$71.33▼$74.1450-Day Range$53.90▼$73.2152-Week Range$11.39▼$74.18Volume1.47 million shsAverage Volume1.26 million shsMarket Capitalization$5.82 billionP/E RatioN/ADividend YieldN/APrice Target$81.50Consensus RatingBuy Company OverviewVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More… Verona Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma scored higher than 58% of companies evaluated by MarketBeat, and ranked 331st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verona Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($1.95) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -37.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -37.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 23.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.22% of the float of Verona Pharma has been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 14.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.22% of the float of Verona Pharma has been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 14.79%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.16 News SentimentVerona Pharma has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Verona Pharma this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $661,854.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Stock News HeadlinesVerona Pharma sees Ohtuvayre sales doubling in Q1 2025, projects expanded sales team by Q3April 30 at 6:35 PM | msn.comVerona Pharma PLC (VRNA) Q1 2025 Earnings Call Highlights: Strong Ohtuvayre Sales Propel ...April 30 at 6:35 PM | finance.yahoo.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 30, 2025 | Paradigm Press (Ad)Verona Pharma plc: Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdateApril 30 at 4:53 AM | finanznachrichten.deVerona Pharma (NASDAQ:VRNA) Now Covered by TD CowenApril 30 at 2:53 AM | americanbankingnews.comVerona Pharma plc (VRNA) Q1 2025 Earnings Call TranscriptApril 29 at 4:16 PM | seekingalpha.comVerona Pharma plc 2025 Q1 - Results - Earnings Call PresentationApril 29 at 3:55 PM | seekingalpha.comVerona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdateApril 29 at 6:00 AM | globenewswire.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $46.44 at the start of the year. Since then, VRNA stock has increased by 55.2% and is now trading at $72.07. View the best growth stocks for 2025 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Tuesday, April, 29th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. Read the conference call transcript. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Verona Pharma's top institutional investors include Allspring Global Investments Holdings LLC (0.70%), Hennion & Walsh Asset Management Inc. (0.25%), GAMMA Investing LLC (0.14%) and Bank of New York Mellon Corp (0.13%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth and Martin Edwards. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings4/29/2025Today4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$79.75 High Stock Price Target$100.00 Low Stock Price Target$57.00 Potential Upside/Downside+10.6%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-2,698.40% Return on Equity-79.54% Return on Assets-43.49% Debt Debt-to-Equity Ratio0.93 Current Ratio13.03 Quick Ratio12.88 Sales & Book Value Annual Sales$42.28 million Price / Sales137.86 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book23.26Miscellaneous Outstanding Shares80,820,000Free Float76,103,000Market Cap$5.83 billion OptionableOptionable Beta0.16 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:VRNA) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.